泮托拉唑、雷尼替丁治疗Hp阳性消化性溃疡对比观察

目的对比观察泮托拉唑与雷尼替丁治疗Hp感染消化性溃疡的临床疗效及不良反应。方法本组94例Hp阳性消化性溃疡患者按随机原则分为观察组和对照组各47例，两组均给予阿莫西林、克拉霉素做为基础治疗，观察组在此基础上加用泮托拉唑40mg，1次／d；对照组加用雷尼替丁150mg，每天早晚各1次，两组均4周为1个疗程。结果观察组Hp清除率93．6％（44／47），溃疡愈合率85．1％（40／47），总有效率95．7％（45／47）；对照组Hp清除率65．9％（31／47），溃疡愈合率63．8％（30／47），总有效率74．5％（35／47），两组临床疗效和Hp清除率比较差异具有统计学意义，χ^2＝4．39，P〈0．05。两组在治疗期间均未出现明显不良反应。结论泮托拉唑联合阿莫西林、克拉霉素治疗Hp阳性消化性溃疡显示出良好的协同作用，临床疗效及Hp清除率明显优于雷尼替丁，且无明显不良反应，临床用药安全。

Contrast observation of helicobacter pylori positive peptic ulcer treated with pantoprazole and ranitidine

Objective A contrast observation of the clinical efficacy and adverse effect of helicobacter pylori （Hp） positive peptic ulcer treated with pantoprazole and ranitidine was conducted. Methods 94 patients with Hp positive peptic ulcer were randomly distributed into experiment group and control group, each were 47 respectively. A baseline therapy of amoxicillin and clarithromycin were given to both groups ; experiment group was additionally given Pantoprazole 40 mg, one time one day, while control group was given Ranitidine 150 mg two times a day. Both groups were treated for 4 weeks as a course. Results Experiment group was favor in Hp clearance （93.6% , 45/47 vs. 65.9% , 31/47） , ulcer healing rate （85.1% , 40/47 vs. 63.8% , 30/47 ） and total effective rate （95.7% , 45/47 vs. 74. 5% , 35/47 ） , and comparisons between clinical efficacy and Hp clearance were of statistical significance （χ^2= 4. 39, P 〈 0. 05 ）. Conclusion A favorable synergetic effect was observed in pantoprazole combined with amoxicillin and clarithromyein. The therapy was superior in clinical efficacy and Hp clearance than ranitidine with no obvious adverse effects, which is safe in clinical practice.